Published: June 07, 2026, 13:15 UTC
The relationship between poor sleep and Alzheimer’s disease is often described as a link, but a new review in Sleep Medicine argues it is more accurate to call it a vicious cycle. Sleep disruption accelerates Alzheimer’s pathology, and Alzheimer’s pathology in turn degrades sleep, creating a self-reinforcing loop driven by a small but powerful group of neurons in the hypothalamus.
The review, led by researchers at China Medical University, focuses on the orexinergic system. Orexin (also known as hypocretin) is a neuropeptide produced by a cluster of neurons in the lateral hypothalamus. It promotes wakefulness, regulates appetite, and modulates arousal. In Alzheimer’s disease, this system goes awry.
The authors synthesize evidence that excessive orexin signaling contributes to insomnia and sleep fragmentation in older adults. Fragmented sleep, in turn, impairs the glymphatic system, the brain’s waste clearance pathway that operates primarily during deep sleep. When glymphatic clearance is compromised, amyloid-beta and tau proteins accumulate more rapidly. Orexin hyperactivity may also activate neurotoxic inflammatory pathways directly, compounding the damage.
The second half of the loop is neurodegenerative. As Alzheimer’s pathology spreads, it damages the brainstem and hypothalamic centers that regulate sleep-wake transitions. This damage makes sleep even more fragmented and unstable, which further impairs clearance and accelerates protein aggregation. The result is a downward spiral: more orexin-driven wakefulness leads to more pathology, which leads to more sleep disruption.
On the therapeutic side, the review points to dual orexin receptor antagonists (DORAs) as a promising intervention. Drugs such as daridorexant and suvorexant, already approved for insomnia, block orexin signaling and promote sleep. If they also reduce orexin-driven pathology, they could serve a dual purpose in older adults at risk for Alzheimer’s. The authors also note intriguing preclinical evidence that Panax ginseng extracts may inhibit orexin signaling and reactivate autophagy through the mammalian target of rapamycin pathway, attenuating neuronal damage in animal models. These findings remain preliminary.
The review has the usual limitations of a narrative synthesis. It is not a systematic review or meta-analysis, and the evidence for some proposed mechanisms is drawn from animal models or correlational human studies. The therapeutic claims about ginseng in particular are based on preclinical data and should be interpreted with caution.
For clinicians, the review highlights a practical point: treating sleep disruption in older adults may be relevant not only for quality of life but also for modifying Alzheimer’s risk. DORAs, already on the market for insomnia, may be worth studying specifically in this population.
Source: Tian Y, Shi Y, Xiong W, et al. The orexinergic crossroads: Bidirectional links between sleep-wake disturbances and the pathogenesis of Alzheimer’s disease in the aging brain. Sleep Medicine, 2026. DOI: 10.1016/j.sleep.2026.109057